NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
Meindl-Beinker, Nadja M.
Betge, Johannes
Gutting, Tobias
Burgermeister, Elke
Belle, Sebastian
Zhan, Tianzuo
Schulte, Nadine
Maenz, Martin
Ebert, Matthias P.
Haertel, Nicolai
BMC CANCER, 2019, 19 (1)
[42] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
Zhang, Bo
Wang, Xi
Zhu, Lingjun
Li, Qun
Liu, Yun
Qi, Ling
Shu, Yongqian
Huang, Jing
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43] A RANDOMISED OPEN-LABEL PHASE I/II STUDY ADDING ONCOS-102 TO PEMETREXED/CISPLATIN IN PATIENTS WITH UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA-24 MONTH SURVIVAL DATA
Jaderberg, Magnus
Paz-Ares, Luis
Cedres, Susana
Ricordel, Charles
Isambert, Nicolas
Aix, Santiago Ponce
Levitsky, Victor
Kuryk, Lukasz
Moller, Anne-Sophie
Vetrhus, Sylvia
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A491 - A491
[44] Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
George, Daniel J.
Spigel, David R.
Gordan, Lucio N.
Kochuparambil, Samith T.
Molina, Ana M.
Yorio, Jeff
Kalebasty, Arash Rezazadeh
McKean, Heidi
Tchekmedyian, Nishan
Tykodi, Scott S.
Zhang, Joshua
Askelson, Margarita
Johansen, Jennifer L.
Hutson, Thomas E.
BMJ OPEN, 2022, 12 (09):
[45] Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma
Fennell, Dean A.
McDowell, Cliona
Busacca, Sara
Webb, Glen
Moulton, Brian
Cakana, Andrew
O'Byrne, Kenneth J.
Meerbeeck, Jan V.
Donnellan, Paul
McCaffrey, John
Baas, Paul
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1466 - 1470
[46] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
Hammers, H.
Sternberg, C.
Mcdermott, D. F.
Larkin, J.
Ravaud, A.
Rini, B.
Sharma, P.
Bhagavatheeswaran, P.
Gagnier, P.
Motzer, R.
BJU INTERNATIONAL, 2014, 114 : 9 - 9
[47] First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Paz-Ares, Luis
Ciuleanu, Tudor-Eliade
Cobo, Manuel
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurelia
Sakai, Hiroshi
Lingua, Alejo
Salman, Pamela
Souquet, Pierre-Jean
De Marchi, Pedro
Martin, Claudio
Perol, Maurice
Scherpereel, Arnaud
Lu, Shue
John, Thomas
Carbone, David P.
Meadows-Shropshire, Stephanie
Agrawal, Shruti
Oukessou, Abderrahim
Yan, Jinchun
Reck, Martin
LANCET ONCOLOGY, 2021, 22 (02): : 198 - 211
[48] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
Callahan, Margaret K.
Bendell, Johanna C.
Chan, Emily
Morse, Michael
Pillai, Rathi Narayana
Bono, Petri
Jaeger, Dirk
Evans, T. R. Jeffry
Chau, Ian
Calvo, Emillano
Le, Dung T.
Ott, Patrick Alexander
Taylor, Matthew Hiram
Sharma, Padmanoo
Antonia, Scott Joseph
Sharkey, Brian
Christensen, Olaf
Amin, Asim
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[49] Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358) a phase 1-2, open-label, multicohort trial
Oaknin, Ana
Moore, Kathleen
Meyer, Tim
Gonzalez, Jose Lopez-Picazo
Devriese, Lot A.
Amin, Asim
Lao, Christopher
Boni, Valentina
Sharfman, William H.
Park, Jong Chul
Tahara, Makoto
Topalian, Suzanne L.
Magallanes, Manuel
Alavez, Alejandro Molina
Khan, Tariq Aziz
Copigneaux, Catherine
Lee, Michelle
Garnett-Benson, Charlie
Wang, Xuya
Naumann, R. Wendel
LANCET ONCOLOGY, 2024, 25 (05): : 588 - 602
[50] VINORELBINE IN MESOTHELIOMA (VIM): A RANDOMISED PHASE II TRIAL OF ORAL VINORELBINE AS SECOND-LINE THERAPY FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) EXPRESSING BRCA1-A STUDY IN PROGRESS
Fennell, D. A.
Casbard, A.
Nixon, L.
Lester, J.
Griffiths, G.
ANNALS OF ONCOLOGY, 2012, 23 : 498 - 498

← 1 2 3 4 5 →